Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 18/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19932625 | 1.00 | CHRM1 (0.44) | CHRM1KMT2APDE2APDE11A | |
| SCHEMBL21545734 | 1.00 | CHRM1 (0.44) | CHRM1KMT2APDE2APDE11A | |
| SCHEMBL19932706 | 0.90 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL21545788 | 0.89 | CHRM1 (0.46) | CHRM1PDE2APDE11A | |
| SCHEMBL19932672 | 0.89 | CHRM1 (0.46) | CHRM1PDE2APDE11A | |
| SCHEMBL21545832 | 0.89 | CHRM1 (0.46) | CHRM1PDE2APDE11A | |
| SCHEMBL21563005 | 0.88 | CHRM1 (0.46) | CHRM1PDE2APDE11A | |
| SCHEMBL21545712 | 0.86 | CHRM1 (0.44) | CHRM1KMT2APDE2APDE11A | |
| SCHEMBL21545743 | 0.86 | CHRM1 (0.44) | CHRM1KMT2APDE2APDE11A | |
| SCHEMBL19932661 | 0.86 | CHRM1 (0.44) | CHRM1KMT2APDE2APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | claimed |
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885KMT2A 2004/4885PDE2A 1330/4885 |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885KMT2A 2004/4885PDE2A 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.